Health Care • Biotechnology: Pharmaceutical Preparations
$95.51 ▼ -1.05
(-1.09%)
MKT CAP: $10.08B • VOL: 752.1K
52W L $21 52W H $110
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$80
MEDIAN
$107
MEAN
$109
HIGH
$130
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SYRE TAPE
SYRE // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $115.57 | $109.84 | 2025-02-14 | $86.91 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $120.34 | $112.70 | 2025-02-06 | $89.78 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $108.88 | $105.06 | 2025-01-29 | $91.69 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $97.42 | — | 2025-01-17 | $93.60 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $84.05 | $90.73 | 2025-01-09 | $85.00 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $113.66 | $99.33 | 2024-12-18 | $83.09 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $92.64 | $96.47 | 2024-12-04 | $88.82 | -4.3% | 48% | C |